文献速递前列腺癌

BRCA1/BRCA2胚系致病变异携带者的靶向前列腺癌筛查:IMPACT研究5年结果

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.
PubMed 文献 · Eur Urol · 2026-02-18

IMPACT研究报告了5轮年度PSA筛查(PSA>3.0 ng/ml时行前列腺活检)的结果,共纳入3063名40-69岁男性,包括BRCA1/BRCA2致病变异携带者及年龄匹配的非携带者。BRCA2携带者临床显著前列腺癌(csPC,GG≥2)发生率显著高于非携带者(3.1% vs 1.3%,p=0.04),且BRCA1/BRCA2携带者中NCCN中危不利/高危肿瘤比例更高。研究建议对BRCA2致病变异携带者行系统性PSA筛查,对BRCA1携带者应考虑筛查。

要点

  • BRCA2携带者csPC发生率显著高于非携带者(3.1% vs 1.3%,p=0.04)
  • BRCA1/BRCA2携带者中NCCN中危不利/高危肿瘤比例显著高于非携带者
  • 建议BRCA2携带者行系统性PSA筛查,BRCA1携带者可考虑筛查

核心结论

  • 年度PSA筛查在BRCA2致病变异携带者中证实csPC发生率更高,并可检出临床相关肿瘤。
  • 首次确认PSA筛查可使BRCA1致病变异携带者的NCCN中危不利/高危前列腺癌获得早期检出。

研究设计与样本

  • IMPACT研究于2005-2015年从20个国家65个中心招募3063名40-69岁(中位54岁)男性。
  • 队列包括915名BRCA1携带者、901名BRCA2携带者,以及727名BRCA1非携带者和520名BRCA2非携带者。
  • 采用年度PSA筛查,PSA>3.0 ng/ml作为前列腺活检指征,报告5轮筛查后结果。

主要发现

  • BRCA1/BRCA2致病变异携带者与非携带者间前列腺癌总体发生率无统计学显著差异。
  • BRCA2携带者csPC发生率显著高于非携带者(3.1% vs 1.3%;p=0.04)。
  • 前列腺癌患者中NCCN中危不利/高危比例:BRCA2组65% vs 32%(p=0.029),BRCA1组56% vs 18%(p=0.0017)。
  • 未发现T4或转移性前列腺癌病例。
  • 根治性前列腺切除术后病理升级:BRCA1携带者7/23(26%),BRCA2携带者10/34(26%),非携带者无肿瘤升级。

关键数值与推荐

  • 活检指征为PSA>3.0 ng/ml。
  • csPC定义为grade group≥2。
  • BRCA2携带者csPC发生率3.1%,非携带者1.3%(p=0.04)。

临床怎么用

  • 对BRCA2致病变异携带者推荐行系统性PSA筛查。
  • 对BRCA1致病变异携带者应考虑行PSA筛查。
  • 筛查中应关注携带者更高的NCCN中危不利/高危肿瘤风险及术后病理升级可能。

局限性

  • 活检依从率存在局限。
  • 2005年以来前列腺癌诊断路径已发生变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: BRCA1 and BRCA2 pathogenic germline variants (PGVs) are associated with higher risk of prostate cancer (PC). The IMPACT study evaluated the utility of targeted prostate-specific antigen (PSA) screening in BRCA1/BRCA2 PGV carriers. Here we report outcomes after five rounds of PSA screening in IMPACT. METHODS: Between 2005 and 2015, 3063 participants aged 40-69 yr (median 54 yr) were recruited from 65 centres in 20 countries in two cohorts: (1) BRCA1/BRCA2 PGV carriers (915 BRCA1, 901 BRCA2); and (2) age-matched noncarriers for a familial PGV (727 BRCA1 and 520 BRCA2 noncarriers). Annual PSA screening was performed, with PSA >3.0 ng/ml used as the indication for prostate biopsy. Our aim was to identify differences by PGV status in (1) the incidence of PC and of clinically significant PC (csPC; grade group ≥2) and (2) tumour stage and characteristics after five screening rounds. KEY FINDINGS AND LIMITATIONS: There was no statistically significant difference in PC incidence between BRCA1/BRCA2 PGV carriers and noncarriers. csPC incidence was significantly higher for BRCA2 PGV carriers than for noncarriers (3.1% vs 1.3%; p = 0.04). Among men with PC, the proportion of tumours with National Comprehensive Cancer Network intermediate unfavourable/high risk was higher in the BRCA1/BRCA2 PGV groups versus the corresponding group without PGVs (BRCA2: 65% vs 32%, p = 0.029; BRCA1: 56% vs 18%, p = 0.0017). There were no T4 or metastatic PC cases. Pathology after radical prostatectomy revealed tumour upgrading for 7/23 (26%) BRCA1 PGV carriers and 10/34 (26%) BRCA2 PGV carriers, with no tumour upgrading for men without PGVs. Study limitations include the biopsy compliance rate and changes in PC diagnostic pathways since 2005. CONCLUSIONS AND CLINICAL IMPLICATIONS: Annual PSA screening in BRCA2 PGV carriers confirmed a higher incidence of csPC and detection of clinically relevant tumours in comparison to noncarriers. For the first time, we confirm that PSA screening in BRCA1 PGV carriers results in early detection of NCCN IR-U/HR PC. Systematic PSA screening is recommended for BRCA2 PGV carriers and should be considered for BRCA1 PGV carriers.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bancroft EK, Page EC, McHugh J, et al. Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study. Eur Urol. 2026. PMID: 41714267. doi:10.1016/j.eururo.2026.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。